Distributor shortlist with reasons
A ranked shortlist per market, with registration status, hospital coverage and reference checks noted for each name.
Your export department
in Central & Eastern Europe
TYMES helps global MedTech manufacturers enter Central & Eastern Europe without building a local operation. We identify and vet distributors, coordinate regulatory requirements, manage commercial negotiations and support the transaction through delivery and after-sales.
Next step
The friction
Sound familiar?
Cold outreach from LinkedIn is full of soft promises. These are the concrete frictions manufacturers hit when entering CEE without a local office.
We do not know whom to trust with our brand and pricing
We have no trusted local partner to manage the market
Counterparties look fine on paper until diligence starts
Registration paths differ by country and nobody owns the file
After-sales disappears once the container lands
No single partner owns the entire U.S.–CEE process
The deliverables
What you receive
A written regulatory route
Per country: EU MDR or national registration, dossier owner, expected timeline and who pays for what.
One commercial counterparty
You invoice an entity based in the USA under United States law. We help reduce and manage the currency, credit and collection exposure downstream.
Market reporting, in writing
Volumes, tender calendar, competitor pricing movement and what changed in regulation — cadence agreed per engagement, always in English and in writing.
Engagement models
How the contract can run
Commission agency
We source and manage the buyer; you contract and invoice the buyer directly. Commission on shipped value.
Buy-sell (EMC of record)
Where legally and operationally available: we purchase on our own account and resell into the market, so you deal with one USA purchase order.
Project engagement
A single tender or hospital project, scoped and priced as a fixed fee plus success component.
Compliance
What we will not do
An intermediary earns trust by naming its limits before a contract, not after one.
We do not misrepresent your product
TYMES does not modify, exaggerate or independently make clinical claims about the products it represents. Product claims remain with the manufacturer and applicable regulatory documentation.
We do not bypass registration
If a device is not registrable in a market on the stated timeline, we say so and stop. No grey-import routes.
We do not sell around your agreed terms
Distributor agreements, pricing floors and territory limits are written and enforceable, or we do not sign them.
We do not run undocumented payments
Written counterparties and document trails are part of every engagement. Settlement follows the contract — through banks and on paper, or not at all.
FAQ
Questions manufacturers ask
Commission agency is our default: you invoice the buyer directly. Under a buy-sell engagement, where available, we purchase on our own account instead. We help reduce and manage cross-border transaction risk either way. We do not invent guarantees we cannot keep.
Sourcing and diligence typically take three to four weeks. Registration is regulator-dependent and often three to eight weeks. We publish indicative ranges and confirm per engagement.
Yes, when written into the agreement. Pricing floors and territory limits are enforceable terms, or we decline the deal.
Due diligence, written counterparties and document trails are part of the engagement. We do not offer grey-import routes or undocumented payments.
When scoped into the deal, yes: instruments are named in the term sheet. Security is a tool to help reduce and manage transaction risk, not a blanket promise.
Sample logistics can be coordinated as part of sourcing and introduction. Criteria for acceptance are written before samples move.
TYMES was founded in 2025 in the United States after roughly fifteen years of medical distribution work in Ukraine. We know how tenders, customs and hospital acceptance actually run.
Next step
Send one page. We will send back a route
Device category, target markets, volume and timeline. That is enough for a first written answer.